Literature DB >> 3403068

Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease.

J W van der Velden1, W L van Putten, V F Guinee, R Pfeiffer, F E van Leeuwen, E A van der Linden, I Vardomskaya, W Lane, M Durand, C Lagarde.   

Abstract

A nested case control study was carried out to investigate the association between treatment of patients with Hodgkin's disease (HD) and the risk of developing acute non-lymphocytic leukemia (ANLL). Seven Cancer Centers of the International Cancer Patient Data Exchange System of the UICC participated. A study cohort was selected consisting of 1,681 nonpretreated patients with HD, diagnosed from 1972 through 1978, and followed up through 1984. The median follow-up time was 66 months. Eighteen cases of leukemia were observed in the cohort. The risk of development of ANLL was significantly greater for male than for female patients. The treatment characteristics associated with an increased risk of developing ANLL were extensive radiotherapy, splenectomy and the chemotherapy combination of vincristine, procarbazine and mechlorethamine.

Entities:  

Mesh:

Year:  1988        PMID: 3403068     DOI: 10.1002/ijc.2910420218

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.

Authors:  Sarah M Lo; Philip Stein; Sean Mullaly; Michael Bar; Dhanpat Jain; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

2.  Development of chronic lymphocytic leukaemia after posttraumatic splenectomy.

Authors:  J Demeter; K Pálóczi; P Vargha; D Lehoczky
Journal:  Blut       Date:  1990-06

3.  Partial splenectomy in children: an alternative for splenectomy in the pathological staging of Hodgkin's disease.

Authors:  H J Hoekstra; R Y Tamminga; W Timens
Journal:  Ann Surg Oncol       Date:  1994-11       Impact factor: 5.344

4.  Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.

Authors:  A J Swerdlow; J A Barber; A Horwich; D Cunningham; S Milan; R Z Omar
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy.

Authors:  A J Swerdlow; A J Douglas; G Vaughan Hudson; B Vaughan Hudson; K A MacLennan
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

6.  Myeloid leukaemia following therapy for a first primary cancer.

Authors:  A Nandakumar; S Davis; S Moolgavkar; R P Witherspoon; S M Schwartz
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.